

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Ivermectin Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Precautionary statements : **Prevention:**
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.

Response:
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) | ENCS No. |
|----------------------------|------------|-----------------------|---------------|
| Ivermectin | 70288-86-7 | $\geq 1 - < 2.5$ | - |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | $\geq 0.1 - < 1$ | 3-540, 9-1805 |

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms : May cause damage to organs if swallowed.

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

and effects, both acute and delayed
Protection of first-aiders : May cause damage to organs through prolonged or repeated exposure if swallowed.
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. |
| Avoidance of contact | : | Oxidizing agents |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

Storage

- | | | |
|-----------------------------|---|--|
| Conditions for safe storage | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Oxidizing solids Oxidizing liquids |
| Packaging material | : | Unsuitable material: None known. |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Concentration standard / Permissible concentration | Basis |
|----------------------------|---------------------------|------------------------------------|---|----------------------|
| Ivermectin | 70288-86-7 | TWA | 30 µg/m3 (OEB 3) | Internal |
| | Further information: Skin | | | |
| | | Wipe limit | 300 µg/100 cm2 | Internal |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | 8h-OEL-M | 10 mg/m3 | JP ISHL OEL 577-2(2) |
| | | TWA (Inhalable fraction and vapor) | 2 mg/m3 | ACGIH |

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

| | | |
|--|---|-----------------------|
| Physical state | : | oily |
| Colour | : | light yellow |
| Odour | : | characteristic |
| Odour Threshold | : | No data available |
| Melting point/freezing point | : | No data available |
| Boiling point, initial boiling point and boiling range | : | 167.5 °C |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Lower explosion limit and upper explosion limit / flammability limit | : | |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Flash point | : | 219.2 °C |
| Decomposition temperature | : | No data available |
| pH | : | No data available |
| Evaporation rate | : | No data available |
| Auto-ignition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | practically insoluble |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Vapour pressure | : | No data available |
| Density and / or relative density | : | |
| Relative density | : | 0.88 - 0.92 |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

| | | |
|--------------------------|---|--|
| Density | : | No data available |
| Relative vapour density | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle characteristics | : | |
| Particle size | : | Not applicable |

10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | Can react with strong oxidizing agents. |
| Conditions to avoid | : | None known. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

11. TOXICOLOGICAL INFORMATION

| | | |
|--|---|--|
| Information on likely routes of exposure | : | Inhalation Skin contact Ingestion Eye contact |
|--|---|--|

Acute toxicity

Not classified based on available information.

Product:

| | | |
|---------------------|---|--|
| Acute oral toxicity | : | Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method |
|---------------------|---|--|

| | | |
|-----------------------|---|--|
| Acute dermal toxicity | : | Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method |
|-----------------------|---|--|

Components:**Ivermectin:**

| | | |
|---------------------|---|---|
| Acute oral toxicity | : | LD50 (Rat): 50 mg/kg LD50 (Mouse): 25 mg/kg LD50 (Monkey): > 24 mg/kg |
|---------------------|---|---|

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Ivermectin:**

Species : Rabbit
Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ivermectin:**

Species : Rabbit
Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ivermectin:**

| | |
|-----------------|--------------------------------------|
| Exposure routes | : Dermal |
| Species | : Humans |
| Result | : Does not cause skin sensitisation. |

2,6-Di-tert-butyl-p-cresol:

| | |
|-----------------|--|
| Test Type | : Human repeat insult patch test (HRIPT) |
| Exposure routes | : Skin contact |
| Species | : Humans |
| Result | : negative |

Germ cell mutagenicity

Not classified based on available information.

Components:**Ivermectin:**

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: human diploid fibroblasts Result: negative |
| | Test Type: Mouse Lymphoma Result: negative |

2,6-Di-tert-butyl-p-cresol:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: In vitro mammalian cell gene mutation test Result: negative |
| | Test Type: Chromosome aberration test in vitro Result: negative |
| Genotoxicity in vivo | : Test Type: Mutagenicity (in vivo mammalian bone-marrow |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Ivermectin:**

| | |
|-------------------|--|
| Species | : Rat |
| Application Route | : Oral |
| NOAEL | : 1.5 mg/kg body weight |
| Result | : negative |
| Remarks | : Based on data from similar materials |

| | |
|-------------------|--|
| Species | : Mouse |
| Application Route | : Oral |
| NOAEL | : 2.0 mg/kg body weight |
| Result | : negative |
| Remarks | : Based on data from similar materials |

2,6-Di-tert-butyl-p-cresol:

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 22 Months |
| Result | : negative |

Reproductive toxicity

Not classified based on available information.

Components:**Ivermectin:**

| | |
|-------------------------------|--|
| Effects on fertility | : Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 0.6 mg/kg body weight Result: Animal testing did not show any effects on fertility. |
| Effects on foetal development | : Test Type: Development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses Test Type: Development Species: Rat |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 9.0 | 2025/04/14 | 6097523-00019 | 2024/09/28 |
| | | | Date of first issue: 2020/06/30 |

Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:**Ivermectin:**

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:**Ivermectin:**

Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Repeated dose toxicity**Components:****Ivermectin:**

| | |
|-------------------|--|
| Species | : Dog |
| NOAEL | : 0.5 mg/kg |
| LOAEL | : 1 mg/kg |
| Application Route | : Oral |
| Exposure time | : 14 Weeks |
| Target Organs | : Central nervous system |
| Symptoms | : Dilatation of the pupil, Tremors, Lack of coordination, anorexia |

| | |
|-------------------|--|
| Species | : Monkey |
| NOAEL | : 1.2 mg/kg |
| Application Route | : Oral |
| Exposure time | : 2 Weeks |
| Remarks | : No significant adverse effects were reported |

| | |
|-------------------|-------------------------------|
| Species | : Rat |
| NOAEL | : 0.4 mg/kg |
| LOAEL | : 0.8 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |
| Target Organs | : spleen, Bone marrow, Kidney |

2,6-Di-tert-butyl-p-cresol:

| | |
|-------------------|-------------|
| Species | : Rat |
| NOAEL | : 25 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 22 Months |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Ivermectin:**

| | |
|--------------|--|
| Skin contact | : Remarks: Can be absorbed through skin. |
| Eye contact | : Remarks: May irritate eyes. |
| Ingestion | : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 9.0 | 2025/04/14 | 6097523-00019 | 2024/09/28 |
| | | | Date of first issue: 2020/06/30 |

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:**Ivermectin:**

| | | |
|---|---|--|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic toxicity) | : | 10,000 |
| M-Factor (Chronic aquatic toxicity) | : | 10,000 |

2,6-Di-tert-butyl-p-cresol:

| | | |
|---|---|---|
| Toxicity to fish | : | LC50 (Danio rerio (zebra fish)): > 0.57 mg/l Exposure time: 96 h Method: Directive 67/548/EEC, Annex V, C.1. |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : | ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic toxicity) | : | 1 |

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

| | |
|--|--|
| Toxicity to fish (Chronic toxicity) | : NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l Exposure time: 30 d Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC (Daphnia magna (Water flea)): 0.316 mg/l Exposure time: 21 d |
| M-Factor (Chronic aquatic toxicity) | : 1 |
| Toxicity to microorganisms | : EC50: > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 |

Persistence and degradability**Components:****Ivermectin:**

| | |
|------------------|--|
| Biodegradability | : Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d |
|------------------|--|

2,6-Di-tert-butyl-p-cresol:

| | |
|------------------|--|
| Biodegradability | : Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C |
|------------------|--|

Bioaccumulative potential**Components:****Ivermectin:**

| | |
|--|-------------------------------------|
| Bioaccumulation | : Bioconcentration factor (BCF): 74 |
| Partition coefficient: n-octanol/water | : log Pow: 3.22 |

2,6-Di-tert-butyl-p-cresol:

| | |
|--|---|
| Bioaccumulation | : Species: Cyprinus carpio (Carp) Bioconcentration factor (BCF): 330 - 1,800 |
| Partition coefficient: n-octanol/water | : log Pow: 5.1 |

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

| | | |
|------------------------|---|---|
| Waste from residues | : | Dispose of in accordance with local regulations. Do not dispose of waste into sewer. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

| | | |
|---------------------------|---|---|
| UN number | : | UN 3082 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| Environmentally hazardous | : | yes |

IATA-DGR

| | | |
|--|---|---|
| UN/ID No. | : | UN 3082 |
| Proper shipping name | : | Environmentally hazardous substance, liquid, n.o.s. (Ivermectin, 2,6-Di-tert-butyl-p-cresol) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | Miscellaneous |
| Packing instruction (cargo aircraft) | : | 964 |
| Packing instruction (passenger aircraft) | : | 964 |
| Environmentally hazardous | : | yes |

IMDG-Code

| | | |
|----------------------|---|---|
| UN number | : | UN 3082 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin, 2,6-Di-tert-butyl-p-cresol) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| EmS Code | : | F-A, S-F |
| Marine pollutant | : | yes |

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Group 4, Type 4 petroleums, (6000 litre), Hazardous rank III

Chemical Substance Control Law

Priority Assessment Chemical Substance

| Chemical name | Number |
|----------------------------------|--------|
| 2,6-Di-tert-butyl-4-methylphenol | 64 |

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

| Chemical name | Concentration (%) | Remarks |
|----------------------------|--------------------|---------|
| 2,6-Di-tert-butyl-4-cresol | ≥ 0.1 - < 1 | - |

Substances Subject to be Indicated Names

Not applicable

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
JP ISHL OEL 577-2(2) : Concentration standard (Value set by the Minister of Health, Labour and Welfare stipulated under the Ministerial Ordinance Article 577-2(2))

ACGIH / TWA : 8-hour, time-weighted average
JP ISHL OEL 577-2(2) / 8h-OEL-M : 8-hour Occupational Exposure Limit-Mean

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-

Ivermectin Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 9.0 | 2025/04/14 | 6097523-00019 | Date of first issue: 2020/06/30 |

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN